COSMO Pharmaceuticals N.V. Logo

COSMO Pharmaceuticals N.V.

Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.

COPN | SW

Overview

Corporate Details

ISIN(s):
NL0011832936
LEI:
724500OX0EBQRYTVV639
Country:
Netherlands
Address:
Sir Rogerson's Quay Riverside II, Dublin 2 Dublin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products for gastroenterology, dermatology, and healthtech. The company's therapeutic focus is on the oral and endoscopic treatment of colon diseases, including bowel diseases and colorectal cancer prevention, utilizing its proprietary MMX® technology. In addition to its own pipeline, Cosmo provides manufacturing services to other pharmaceutical companies. These services cover the production of solid, semi-solid, and liquid oral medicines and include process assessment, technology transfer, stability testing, market release, and regulatory documentation support.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-21 02:00
Regulatory News Service
Cosmo Pharmaceuticals receives regulatory approval by the European Commission f…
English 6.1 KB
2025-10-21 02:00
Regulatory News Service
Cosmo Pharmaceuticals erhält nach positiver Stellungnahme des CHMP die behördli…
German 7.2 KB
2025-10-07 02:00
Regulatory News Service
Cosmo Pharmaceuticals announces regulatory approval of Winlevi® in South Korea
English 5.2 KB
2025-10-07 02:00
Regulatory News Service
Cosmo Pharmaceuticals gibt die behördliche Zulassung von Winlevi® in Südkorea b…
German 6.2 KB
2025-08-27 02:00
Regulatory News Service
Cosmo Receives Positive CHMP Opinion for Winlevi® for Treatment of Acne in Adul…
English 7.4 KB
2025-08-27 02:00
Regulatory News Service
Cosmo erhält positive CHMP-Stellungnahme für Winlevi® zur Behandlung von Akne b…
German 8.8 KB
2025-08-08 02:00
Regulatory News Service
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of O…
English 4.7 KB
2025-08-08 02:00
M&A Activity
Cosmo und Takeda verlängern ihre strategische Produktionsvereinbarung für die w…
German 5.0 KB
2025-08-06 02:00
Business and Financial Review
Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffir…
English 3.3 KB
2025-08-06 02:00
Earnings Release
Cosmo Pharmaceuticals bestätigt, dass keine Auswirkungen durch geplante US-Zöll…
German 4.0 KB
2025-07-23 02:00
Earnings Release
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance …
English 22.3 KB
2025-07-23 02:00
Earnings Release
Cosmo liefert starke Ergebnisse im ersten Halbjahr 2025, erhöht EBITDA-Guidance…
German 24.4 KB
2025-07-17 02:00
Regulatory News Service
Cosmo announces launch of Winlevi® for Treatment of Acne in Singapore and Malay…
English 9.5 KB
2025-07-17 02:00
Regulatory News Service
Cosmo: Markteinführung von Winlevi® zur Behandlung von Akne in Singapur und Mal…
German 10.7 KB
2025-07-16 02:00
Environmental & Social Information
Cosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact…
English 6.4 KB

Automate Your Workflow. Get a real-time feed of all COSMO Pharmaceuticals N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for COSMO Pharmaceuticals N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for COSMO Pharmaceuticals N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
REYON PHARMACEUTICAL CO., LTD Logo
Develops & makes APIs, generics, cell/gene therapies, and offers biopharma CDMO services.
South Korea 102460
Roche Holding AG Logo
A global leader in pharmaceuticals and diagnostics, pioneering personalized healthcare solutions.
Switzerland RO
ROHTO PHARMACEUTICAL CO.,LTD. Logo
Manufactures OTC drugs, skincare, and cosmetics with a focus on eye and dermatological health.
Japan 4527
RPbio Inc. Logo
A global CDMO specializing in soft capsules, pharmaceuticals, and health functional foods.
South Korea 314140
Develops and produces IVD kits and biological pharmaceuticals for the healthcare sector.
Türkiye RTALB
SAMIL PHARMACEUTICAL CO.,LTD Logo
Develops & manufactures drugs for eye & liver diseases, with a broad portfolio & CDMO services.
South Korea 000520
SAMJIN PHARMACEUTICAL CO.,LTD Logo
Researches & develops drugs for cardiovascular, respiratory, and gastrointestinal disorders.
South Korea 005500
SAMSUNG BIOLOGICS CO.,LTD. Logo
A CDMO providing end-to-end development and manufacturing services for the biopharma industry.
South Korea 207940
SanBio Company Limited Logo
Developing regenerative cell therapies for severe neurological disorders like brain injury and stroke.
Japan 4592
SANIGEN Co., Ltd. Logo
Provides food safety solutions and genetic diagnostics for the entire food industry.
South Korea 188260

Talk to a Data Expert

Have a question? We'll get back to you promptly.